EpiSign

Greenwood Diagnostic Laboratories in partnership with London Health Science Centre present EpiSign!

GGC Launches EpiSign, a Novel Clinical Test for Epigenetic Changes
GGC Launches EpiSign, a Novel Clinical Test for Epigenetic Changes

EpiSign is an assay designed to readily identify proven and reproducible epigenetic signatures by assessing genome-wide methylation.

EpiSign has multiple applications in the clinical setting by providing an additional diagnostic tool beyond the current sequencing and copy number             technology paradigm.  EpiSign can detect multiple methylation abnormalities associated with certain imprinting or triplet repeat conditions. This test can also identify disease-specific methylation patterns involving multiple loci across the genome. 

Assessment of these distinct methylation patterns can be a useful screening tool for these disorders in the diagnostic work-up or can be applied in a more targeted fashion to help resolve variants of uncertain clinical significance.

Version 2 launched in 2020 increasing the number of identifiable disorders from 19 to 40.


One Assay. Two Options.

Episign is offered as two different tests to suit the needs of your patient.

  • EpiSign Complete v.2 
    A comprehensive analysis including 40 disorders.
  • EpiSign Variant   
    A targeted review of the methylation data intended to resolve variants of uncertain clinical signficance. 

Meet the Shenal Family

Our daughter, Ryleigh, was diagnosed with a rare chromosomal deletion shortly after she was born in 2010. Since we received her diagnosis, the Greenwood Genetic Center has become part of our family. They made certain that we did not feel alone, and they continue to provide ongoing, compassionate care for our child. The impact they have had on our family and others across the globe everyday is immeasurable. We can't imagine walking this journey without...

In The News